Loading Page
Dr. Liora Michal Schultz, MD is a physician provider in New York, NY specializing in physician and pediatric hematology/oncology. She graduated from University of Toronto Faculty of Medicine. Dr. Liora Michal Schultz, MD is affiliated with NewYork-Presbyterian, ColumbiaDoctors and CUIMC/NewYork-Presbyterian Morgan Stanley Children's Hospital.
Dr. Liora Michal Schultz, MD graduated from University of Toronto Faculty of Medicine. She completed residency at New York-Presbyterian Hospital. She is certified by the Board Certification: pediatrics hematology /oncology and has a state license in New York.
Medical School: University of Toronto Faculty of Medicine
Residency: New York-Presbyterian Hospital
Board Certification: Board Certification: pediatrics hematology /oncology
Licensed In: New York
Dr. Liora Michal Schultz, MD appears to accept the following insurance providers: VNSNY CHOICE, CIGNA, Healthspring (Cigna Medicare), Local 1199, Empire Blue Cross/Blue Shield, Emblem/GHI, Medicare, Affinity Health Plan, Amida Care, UnitedHealthcare, Empire Blue Cross Blue Shield Healthplus, Emblem/Hip, Fidelis Care, MVP Health Care, WellCare, World Trade Center Health Plan, Magnacare (National), AETNA, Multiplan, Healthfirst, MultiPlan, United Healthcare PPO, United Healthcare POS, United Healthcare HMO, Aetna POS, MVP Health Care, MagnaCare, Vytra, Great-West Healthcare, Healthfirst, Aetna EPO, Aetna PPO, Aetna HMO, GHI PPO, Group Health Incorporated (GHI), Aetna Signature Administrators, CIGNA PPO, CIGNA POS, CIGNA HMO, CIGNA EPO, EmblemHealth, WellCare, Medicaid Managed Care, Blue Shield PPO, Blue Shield HMO, Blue Shield EPO, HealthSpring, UnitedHealthcare, Affinity Health Plan, United Healthcare, Medicare, Medicaid, Cigna, 1199SEIU, Oxford HMO, Fidelis Care, HIP PPO, HIP POS, HIP EPO, HIP HMO, Empire BlueCross BlueShield HMO, Empire BlueCross BlueShield PPO, Empire BlueCross BlueShield, Aetna, Healthfirst - Leaf (Exchange), AETNA - Student Health, MVP Health Care - Child/Family Health Plus, Healthfirst - Child/Family Health Plus, Empire Blue Cross - EPO, AETNA - NY Signature, Amida Care - Special Needs, AETNA - Medicare Managed Care, Healthfirst - Medicare Managed Care, VNSNY CHOICE - SelectHealth, VNSNY CHOICE - Medicare Managed Care, MVP Health Care - Essential Plan, World Trade Center Health Plan - World Trade Center Health Plan, Medicare - Traditional Medicare, VNSNY CHOICE - Special Needs and MVP Health Care - HMO.
According to our sources, Dr. Liora Michal Schultz, MD accepts the following insurance providers:
Dr. Liora Michal Schultz, MD does not have any reviews yet, be the first to leave a review of Dr. Liora Michal Schultz, MD here: Leave a Review
These charts describe general payments received by Dr. Liora Michal Schultz, MD. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
|
$3,173
KYMRIAH $3,032 |
RYDAPT $16 |
$125 |
|
|
$2,903
IMBRUVICA $2,903 |
|||
|
$205
clonoSEQ $205 |
| $2,820 | |
| $2,688 | |
| $773 |
Dr. Liora Michal Schultz, MD has received 13 research payments totaling $112,297.
Dr. Liora M. Schultz is an Associate Professor of Pediatrics at Columbia University Irving Medical Center, where she directs the Pediatric Cellular Immunotherapy Program and serves as Founding Director of the Pediatric Real-World CAR Consortium. She is board certified in Pediatrics and Pediatric Hematology/Oncology.Dr. Schultz completed her pediatric residency at NewYork-Presbyterian/Weill Cornell Medical Center and her fellowship in Pediatric Hematology/Oncology at Memorial Sloan Kettering Cancer Center. She subsequently pursued a postdoctoral fellowship in Immunotherapy at Stanford University School of Medicine.Her clinical and research work focuses on pediatric hematologic and oncologic malignancies, with a particular emphasis on advancing immunotherapeutic approaches for children with cancer. Through her leadership in clinical innovation and collaborative research, Dr. Schultz aims to expand access to and improve outcomes of cellular therapies in the pediatric population.
